Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
Status:
Not yet recruiting
Trial end date:
2023-12-10
Target enrollment:
Participant gender:
Summary
The purpose is to evaluate the effectiveness and safety of Surufatinib in patients with
osteosarcoma and soft tissue sarcoma after Standard chemotherapy therapy.